Soluble bio-markers in vascular disease: Much more than gauges of disease?

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 4, 2005, Pages 233-240

  Woollard, Kevin J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

C reactive protein; Cell adhesion molecules; Inflammation; Leukocytes; P selectin; Vascular disease

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PADGEM PROTEIN;

CELL INTERACTION; DISEASE ACTIVITY; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN BINDING; SHORT SURVEY; VASCULAR DISEASE;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION; HUMANS; INFLAMMATION; LEUKOCYTE ROLLING; LEUKOCYTES; MODELS, BIOLOGICAL; P-SELECTIN; VASCULAR DISEASES;

EID: 17844399514     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04178.x     Document Type: Short Survey

References (71)

1. Ross R. Atherosclerosis is an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
2. Rainer Z. Pathophysiology and classification of cardiovascular diseases caused by atherosclerosis. J. Int. Fed. Clin. Chem. Lab. Med. 2001; 13: 1-4.
3. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001; 89: 763-71.
4. Huo Y, Ley K. Adhesion molecues and atherogenesis. Acta Physiol. Scand. 2001; 173: 35-43.
5. Kuller LH. Prevention of cardiovascular disease and the future of cardiovascular disease epidemiology. Int. J. Epidemiol. 2001; 30: 66-72.
6. Hope SA, Meredith JT. Cellular adhesion molecules and cardiovascular diseases. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern. Med. J. 2003; 33: 450-62.
7. Camici M, Sagripanti A. Cardiovascular prevention: New biochemical plasmatic markers or risk. Minerva Med. 2002; 93: 275-86.
8. Lowe GD. The relationship between infection, inflammation and cardiovascular disease epidemiology. Ann. Periodontol. 2001; 6: 1-8.
9. Tokac M, Ozeren A, Aktan M et al. The role of inflammation markers in triggering acute coronary events. Heart Vessels 2003; 18: 171-6.
10. Tillet W, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the Pneumococcus. J. Exp. Med. 1930; 52: 561-71.
11. Szalaia A, Van Ginkel F, Wang Y, McGhee J, Volanakis J. Complement-dependent acute phase expression of C-reactive protein and serum amyloid P-component. J. Immunol. 2000; 165: 1030-5.
12. Ramji D, Vitelli A, Tronche F, Cortese R, Ciliberto G. The two C/EBP isoforms, IL-6DBP/NF-IL-6 and C/EBP delta/NF-IL-6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids. Res. 1993; 21: 289-94.
13. Macintyre S, Samols D, Daily P. Two carboxylesterases bind C-reactive protein within the endoplasmic reticulum and regulate its secretion during the acute phase response. J. Biol. Chem. 1994; 269: 24496-503.
14. Yue C, Muller-Greven J, Dailey P, Lozanski G, Anderson V, Macintyre S. Identification of a C-reactive protein binding site in two hepatic carboxylesterases capable of retaining C-reactive protein within the endoplasmic reticulum. J. Biol. Chem. 1996; 271: 22 245-50.
15. Du Clos TW, Mold C. The role of C-reactive protein in the resolution of bacterial infection. Curr. Opin. Infect. Dis. 2001; 3: 289-93.
16. Haverkate F, Thompson S, Puke S, Gallimore R, Pepys M. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
17. Koeing W, Sund M, Frhlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-1992. Circulation 1999; 99: 237-42.
18. Tommasi S, Carluccio E, Bentivoglio M et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first uncomplicated myocardial infarction. Am. J. Cardiol. 1999; 83: 1595-9.
19. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N. Engl. J. Med. 2000; 343: 1139-47.
20. Hokama Y, Coleman M, Riley R. In vitro effects of C-reactive protein on phagocytosis. J. Bacteriol. 1962; 83: 1017-24.
21. Marnell L, Mold C, Volzer M, Burlingame R, Du Clos T. C-reactive protein binds to FcγRI in transfected COS cells. J. Immunol. 1995; 155: 2185-93.
22. Bhardwaj D, Stein M, Volzer M, Mold C, Du Clos T. C-reactive protein binds to FcγRIIa-transfected COS cells. J. Exp. Med. 1999; 190: 585-91.
23. Stein M, Mold C, Du Clos T. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J. Immunol. 2000; 164: 1514-20.
24. Mortensen R, Duszkiewcz J. Mediation of CRP-dependent phagocytosis through mouse macrophage Fc-receptors. J. Immunol. 1997; 119: 1611-16.
25. Kilpatrick J, Volanakis J. Opsonic properties of C-reactive protein: Stimulation by phorbol myristate ecetate enables human neutrophils to phagocytize C-reactive protein-coated cells. J. Immunol. 1985; 134: 3364-70.
26. Edwards K, Gewurz H, Lint T, Mold C. A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27 Streptococcus pneumoniae. J. Immunol. 1982; 128: 2493-6.
27. Barna B, James K, Deodhar S. Activation of human monocyte tumorcidal activity by C-reactive protein. Cancer Res. 1987; 47: 3959-63.
28. Tebo J, Mortensen R. Internalisation and degradation of receptor bound C-reactive protein by U937 cells: Induction of H2O2 production and tumorcidal activity. Biochem. Biophys. Acta 1991; 1095: 210-16.
29. Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, Dayer J. C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. J. Leukoc. Biol. 1993; 53: 439-45.
30. Zouki C, Beauchamp M, Baron C, Filep J. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest. 1997; 100: 522-9.
31. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 2349-54.
32. Jones S, Novick D, Horiuchi S. C-reactive protein: A physiological activator of interleukin-6 receptor shedding. J. Exp. Med. 1999; 189: 599-605.
33. Borish LC, Steinke JW. Cytokines and chemokines. J. Allergy Clin. Immunol. 2003; 111: 460-75.
34. Tarda K, Honda S, Hanakahi L, Nakate M, Nakagawa L, Hokama Y. Direct CRP binding to human monocytes and enhanced IL-1 synthesis induced by CRP-PAF complexes. FASEB J. 1988; J2: A685.
35. Barna B, Thomassen M, Clements M, Deodhar S. Cytokine induction associated with human C-reactive protein. FASEB J. 1989; J3: A824.
36. Suthun P, Katsura K, Hokama Y. Effect of C-reactive protein (CRP) and platelet activating factor (PAF) on tumour necrosis factor (TNF) synthesis in monocytes. FASEB J. 1990; J4: A1037.
37. Yamada Y, Kimball K, Okusawa S et al. Cytokines, acute phase proteins, and tissue injury. Ann. N.Y. Acad. Sci. 1990; 587: 351-61.
38. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-8.
39. Mold C, Rodriguez W, Rodic-Polic B, Du Clos T. C-reactive protein mediates protection from lipopolysaccharide through interactions with FcγR. J. Immunol. 2002; 169: 7019-25.
40. Szalai A, Nataf S, Hu X, Barnum S. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol. 2002; 168: 5792-9.
41. Woollard KJ, Phillips DC, Griffiths HR. Direct modulatory effect of C-reactive protein on primary monocyte adhesion to human endothelial cells. Clin. Exp. Immunol. 2002; 130: 256-62.
42. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336: 973-9.
43. Butke T, Sandstrom P. Oxidative stress as a mediator of apoptosis. Immunol. Today 1994; 15: 7-10.
44. Khatri JJ, Johnson C, Magid R et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109: 520-5.
45. Dobrinch R, Spagnuolo PJ. Binding of C-reactive protein to human neutrophils: Inhibition of respiratory activity. Arthritis. Rheum. 1991; 34: 1031-6.
46. Buchta R, Fridkin M, Pontet M, Contessi E, Scaggiante S, Romeo D. Modulation of human neutrophil function by C-reactive protein. Eur. J. Biochem. 1987; 163: 141-9.
47. Barna B, Deodhar S, Gautam S, Yen-Lieberman B, Roberts D. Macrophage activation and generation of tumorcidal activity by liposome-associated human C-reactive protein. Cancer Res. 1984; 44: 305-11.
48. Chi M, Tridandapani S, Zhong W, Coggeshall K, Mortensen R. C-reactive protein induces signaling through FcγRIIa on HL60 granulocytes. J. Immunol. 2002; 168: 1413-18.
49. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-101.
50. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J. Clin. Invest. 1997; 100: 2085-93.
51. Palabrica T, Lobb R, Furie BC et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
52. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-57.
53. Frenette PS, Denis CV, Weiss L et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J. Exp. Med. 2000; 191: 1413-22.
54. Ramachandran V, Yago T, Epperson TK et al. Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow. Proc. Natl Acad. Sci. USA 2001; 98: 10 166-71.
55. Epperson TK, Patel KD, McEver RP, Cummings RD. Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin. J. Biol. Chem. 2000; 275: 7839-53.
56. Yang J, Hirata T, Croce K et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J. Exp. Med. 1999; 190: 1769-82.
57. Evangelista V, Manarini S, Coller BS, Smyth SS. Role of P-selectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion. Thromb. Haemost. 2003; 1: 1048-54.
58. Urzainqui A, Serrador JM, Viedma F et al. ITAM-based interaction of ERM proteins with Syk mediates signalling by the leukocyte adhesion receptor PSGL-1. Immunity 2002; 17: 401-12.
59. Simon SI, Goldsmith HL. Leukocyte adhesion dynamics in shear flow. Ann. Biomed. Eng. 2002; 3: 315-32.
60. Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol Rev. 2002; 186: 141-63.
61. Michelson AD, Barnard MR, Hechtman HB et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc. Natl Acad. Sci. USA 1996; 93: 11 877-82.
62. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
63. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: Implications for atherogenesis? A preliminary report. J. Hypertens. 1995; 13: 1674-8.
64. Davi G, Romano M, Mezzetti A et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-7.
65. Shimomura H, Ogawa H, Arai H et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am. J. Cardiol. 1998; 15: 397-400.
66. Mehta P, Patel KD, Laue TM, Erickson HP, McEver RP. Soluble monomeric P-selectin containing only the lectin and epidermal growth factor domains binds to P-selectin glycoprotein ligand-1 on leukocytes. Blood 1997; 90: 2381-9.
67. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Procoagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl Acad. Sci. USA 2000; 97: 13 835-40.
68. Myers DD, Hawley AE, Farris DM et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J. Vasc. Surg. 2003; 38: 1075-89.
69. Hrachovinova I, Cambien B, Hafezi-Moghadam A et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. 2003; 9: 1020-5.
70. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 2001; 86: 746-56.
71. Gamble JR, Skinner MP, Berndt MC, Vadas MA. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP-140. Science 1990; 249: 414-17.